Connection

Mark Rubinstein to Immunotherapy

This is a "connection" page, showing publications Mark Rubinstein has written about Immunotherapy.
Connection Strength

1.424
  1. IL-2 and Beyond in Cancer Immunotherapy. J Interferon Cytokine Res. 2018 02; 38(2):45-68.
    View in: PubMed
    Score: 0.529
  2. IL-2Ra mediates temporal regulation of IL-2 signaling and enhances immunotherapy. Sci Transl Med. 2015 Oct 28; 7(311):311ra170.
    View in: PubMed
    Score: 0.452
  3. Converting Tumoral PD-L1 into a 4-1BB Agonist for Safer and More Effective Cancer Immunotherapy. Cancer Discov. 2022 05 02; 12(5):1184-1186.
    View in: PubMed
    Score: 0.178
  4. Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing. J Hematol Oncol. 2018 12 21; 11(1):142.
    View in: PubMed
    Score: 0.141
  5. Review: novel nonviral delivery approaches for interleukin-12 protein and gene systems: curbing toxicity and enhancing adjuvant activity. J Interferon Cytokine Res. 2006 Sep; 26(9):593-608.
    View in: PubMed
    Score: 0.060
  6. Fueling Cancer Immunotherapy With Common Gamma Chain Cytokines. Front Immunol. 2019; 10:263.
    View in: PubMed
    Score: 0.036
  7. Exploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinic. Cancer Immunol Immunother. 2016 Mar; 65(3):247-59.
    View in: PubMed
    Score: 0.029
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.